A Phase I, Dose Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Daily Subcutaneous Injections in Adult Patients With Solid Tumors

Trial Profile

A Phase I, Dose Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Daily Subcutaneous Injections in Adult Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2008

At a glance

  • Drugs Iboctadekin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Oct 2008 Actual start date (Jan 2003) added as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jul 2008 Actual patient number (25) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top